Castle Biosciences (NASDAQ:CSTL) Earns Outperform Rating from Analysts at Svb Leerink

Svb Leerink started coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a research report report published on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $28.00 price target on the stock. Svb Leerink also issued estimates for Castle Biosciences’ Q2 2019 earnings at ($0.44) EPS, Q3 2019 earnings at ($0.27) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.23) EPS, Q1 2020 earnings at ($0.30) EPS, Q2 2020 earnings at ($0.36) EPS, Q3 2020 earnings at ($0.30) EPS, Q4 2020 earnings at ($0.33) EPS, FY2020 earnings at ($1.29) EPS and FY2021 earnings at ($0.42) EPS.

A number of other research firms have also recently commented on CSTL. Robert W. Baird initiated coverage on shares of Castle Biosciences in a research note on Monday. They set an outperform rating and a $27.00 target price on the stock. Leerink Swann initiated coverage on shares of Castle Biosciences in a research note on Monday. They set an outperform rating and a $28.00 target price on the stock. Finally, Canaccord Genuity initiated coverage on shares of Castle Biosciences in a research note on Monday. They set a buy rating and a $26.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, Castle Biosciences currently has an average rating of Buy and a consensus target price of $26.80.

NASDAQ CSTL opened at $22.75 on Monday. Castle Biosciences has a 12 month low of $17.11 and a 12 month high of $24.75.

In related news, major shareholder Mgc Venture Partners 2013 Gp, acquired 312,500 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David S. Kabakoff acquired 62,500 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The shares were bought at an average price of $16.00 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here.

About Castle Biosciences

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

See Also: Overbought

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit